Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C~* Male and female subjects, 18 to 70 years of age, inclusive~* Genotype 1, chronic hepatitis C with detectable HCV RNA.~* Screening laboratory values, tests, and physical exam within acceptable ranges~* Able and willing to follow contraception requirements~* Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions.~Exclusion Criteria:~* Subject has any contraindications to Pegasys® or Copegus® therapy~* Evidence of hepatic decompensation in cirrhotic subjects~* History of organ transplant~* History of, or any current medical condition which could impact the safety of the subject in participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- T12PR24 (eRVR+) (Type: EXPERIMENTAL): Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
- T12PR48 (eRVR+) (Type: EXPERIMENTAL): Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
- T12PR48 (eRVR-) (Type: EXPERIMENTAL): Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
- Other (Type: EXPERIMENTAL): Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).